Fundamental analysis of $BCTXZ (BriaCell Therapeutics Corp.) based on financial data and reported results.

#BCTXZ #BriaCell

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient BriaCell (Nasdaq: BCTX) reported an 11-month sustained complete resolution of a lung metastasis in the first patient enrolled in the Bria-OTS Phase 1/2a metastatic breast cancer study.The 78-year-old hormone receptor-positive, HER2-negative patient achieved 100% resolution after four doses of Bria-OTS monotherapy, with the response first seen at 2 months and confirmed at 4, 6, and 11 months; the patient completed 12 months on study, received 17 cycles, reported no treatment-limiting toxicities, maintained stable disease at other evaluable sites, and remains in survival follow-up.The Phase 1 dose-escalation is complete and the Phase 2a combination study with an immune checkpoint inhibitor is underway.

#BCTX #BCTXW #BCTXZ BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

www.stocktitan.net/news/BCTX/bria-cell-repo...

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine BriaCell (Nasdaq: BCTX) announced its Phase 3 Bria-IMT trial in metastatic breast cancer (BRIA-ABC) was highlighted in Nature Medicine’s "Eleven clinical trials that will shape medicine in 2026."The company said the trial has screened more than 230 patients and enrolled over 160 patients, with an interim analysis scheduled once 144 patient events (deaths) occur. BriaCell anticipates reporting topline data as early as H1-2026. The Bria-IMT combination has FDA Fast Track designation. The primary endpoint at interim is overall survival comparing Bria-IMT plus checkpoint inhibitor versus physician’s choice.

#BCTX #BCTXW #BCTXZ “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

www.stocktitan.net/news/BCTX/eleven-clinica...

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ®) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell’s regimen Maturing Phase 2

#BCTX #BCTXW #BCTXZ BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

www.stocktitan.net/news/BCTX/bria-cell-pres...

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout BriaCell (Nasdaq: BCTX) reported that its pivotal Phase 3 study in metastatic breast cancer has screened >230 patients and enrolled >160, with enrollment exceeding expectations and strong site/patient interest.The company expects a topline interim data readout as early as 1H2026; the interim analysis will occur once 144 patient events (deaths) are observed and will assess overall survival (OS) versus physician’s choice. The Phase 3 regimen retains FDA Fast Track designation and positive results could support full approval and marketing authorization for Bria-IMT.

#BCTX #BCTXW #BCTXZ BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

www.stocktitan.net/news/BCTX/bria-cell-s-ph...

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 BriaCell (Nasdaq: BCTX) will present three posters at the San Antonio Breast Cancer Symposium on December 10, 2025 highlighting positive Phase 2 safety and efficacy signals, positive biomarker findings, and survival data.The company said its pivotal Phase 3 Bria-IMT+CPI trial is ongoing with an interim analysis expected in H1 2026. The Bria-IMT regimen has received Fast Track designation from the US FDA. Abstract and poster copies will be available on the company's scientific publications webpage.

#BCTX #BCTXW #BCTXZ BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

www.stocktitan.net/news/BCTX/bria-cell-to-h...

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro's small-molecule pipeline Aims to accelerate the development of next generation therapeutics with improved efficacy

#BCTX #BCTXW #BCTXZ BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

www.stocktitan.net/news/BCTX/bria-cell-and-...

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025 Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer) Preclinical data reinforces broad

#BCTX #BCTXW #BCTXZ BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

www.stocktitan.net/news/BCTX/bria-cell-pres...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer BriaCell (NASDAQ: BCTX) said an independent Data Safety Monitoring Board issued its fourth consecutive positive recommendation after reviewing safety data from the pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer (NCT06072612). The DSMB identified no safety concerns and recommended the study continue without modifications. The study is conducted under FDA Fast Track designation. DSMB meetings occur quarterly; this is the fourth positive quarterly review. Management highlighted confidence in the regimen's safety and tolerability and reiterated commitment to advancing the trial for patients with urgent unmet needs.

#BCTX #BCTXW #BCTXZ BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-rece...

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study BriaCell (Nasdaq: BCTX) added Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University to its pivotal Phase 3 metastatic breast cancer study (ClinicalTrials.gov NCT06072612).The trial now has 79 clinical sites across 23 US states enrolling patients and evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice. Interim analysis is planned once 144 patient events (deaths) occur, and the company anticipates reporting top-line data as early as H1-2026. The Bria-IMT regimen holds FDA Fast Track designation.

#BCTX #BCTXW #BCTXZ BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

www.stocktitan.net/news/BCTX/bria-cell-adds...

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer BriaCell (Nasdaq: BCTX) announced a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator to support the development of Bria-OTS+, including Bria-BRES+ for metastatic breast cancer, on October 21, 2025. The agreement covers manufacturing, IND preparation and clinical protocol support aimed at enabling a Phase 1 clinical trial.The partnership gives BriaCell access to MSK’s institutional expertise in cell therapy manufacturing and clinical development to expedite Bria-OTS+ advancement into the clinic.

#BCTX #BCTXW #BCTXZ BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-anno...

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025 BriaCell (Nasdaq: BCTX) presented biomarker data from its ongoing pivotal Phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer at ESMO 2025 (poster #3928).Pooled, blinded data from 113 patients (median 6 prior lines) show biomarker trends consistent with Phase 2: neutrophil-to-lymphocyte ratio (NLR) remains a potential predictor of clinical benefit (Phase 2 PFS 4.5 vs 2.5 months; HR 0.5, 95% CI 0.3–0.8, p=0.005). No new safety or tolerability signals were identified and there were no treatment-related discontinuations.Interim OS analysis is planned at 144 events. Bria-IMT combination has FDA Fast Track designation.

#BCTX #BCTXW #BCTXZ BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

www.stocktitan.net/news/BCTX/bria-cell-pres...

Breakthrough Cancer Treatment Mechanism: BriaCell and NCI Validate Novel Immunotherapy Platform in Major Study BriaCell and NCI research confirms mechanism of Bria-OTS+ personalized immunotherapy platform. Study shows enhanced tumor-antigen presentation and CD4+ T-cell responses in cancer treatment.

#BCTX #BCTXW #BCTXZ BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

www.stocktitan.net/news/BCTX/bria-cell-s-br...

BriaCell Announces Proposed Effective Date of Share Consolidation BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation (reverse stock split) to maintain Nasdaq listing compliance. The consolidation is set to take effect on August 25, 2025.Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted.Post-consolidation, BriaCell will continue trading under the symbols BCT on TSX and BCTX on Nasdaq. Registered shareholders will receive transmittal letters from Computershare Investor Services with exchange instructions.

#BCTX #BCTXW #BCTXZ BriaCell Announces Proposed Effective Date of Share Consolidation

www.stocktitan.net/news/BCTX/bria-cell-anno...

Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program BriaCell's personalized off-the-shelf immunotherapy platform gains support from leading cancer center MSK for accelerated development across multiple cancer types. Learn more.

#BCTX #BCTXW #BCTXZ BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

www.stocktitan.net/news/BCTX/bria-cell-sele...

BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know BriaCell plans 10:1 share consolidation effective August 25. Learn how this reverse split impacts your holdings and trading timeline. Get complete details.

#BCTX #BCTXW #BCTXZ BriaCell Announces Proposed Effective Date of Share Consolidation

www.stocktitan.net/news/BCTX/bria-cell-anno...

BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment New Zealand patent grant extends BriaCell's whole-cell cancer vaccine technology protection until 2037. Discover how this precision medicine approach transforms cancer care.

#BCTX #BCTXW #BCTXZ BriaCell Awarded New Zealand Patent for its Whole Cell Technology

www.stocktitan.net/news/BCTX/bria-cell-awar...

Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously Novel TILsRx platform enables targeted treatment of multiple cancers including prostate, lung, and breast. Discover how this breakthrough technology transforms immunotherapy. Learn more.

#BCTX #BCTXW #BCTXZ BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

www.stocktitan.net/news/BCTX/bria-cell-s-su...

BriaCell to Reveal Pivotal Phase III Breast Cancer Trial Results at Major ESMO Conference Latest Phase III trial data for Bria-IMT immunotherapy in metastatic breast cancer to be unveiled at ESMO 2025. Get exclusive insights into trial outcomes.

#BCTX #BCTXW #BCTXZ BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

www.stocktitan.net/news/BCTX/bria-cell-anno...

Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors BriaCell prices public offering at $1.25 per unit to advance novel cancer immunotherapies. Includes warrants at $1.50 exercise price. See full offering terms.

#BCTX #BCTXW #BCTXZ BriaCell Therapeutics Announces Pricing of $15 million Public Offering

www.stocktitan.net/news/BCTX/bria-cell-ther...

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer BriaCell Therapeutics (NASDAQ: BCTX) has announced the addition of Mayo Clinic as a clinical site for its pivotal Phase 3 study in metastatic breast cancer. The study now encompasses 69 active clinical sites across 15 states.The Phase 3 trial is evaluating Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer. The study's primary endpoint will analyze interim data after 144 patient events (deaths), comparing overall survival between treatment groups. The company recently reported positive Phase 2 survival data at ASCO 2025, and the Bria-IMT combination regimen has received FDA Fast Track designation.

#BCTX #BCTXW #BCTXZ BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-adds...

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer BriaCell Therapeutics (NASDAQ: BCTX) has reported promising Phase 2 survival data for its Bria-IMT™ immunotherapy in combination with checkpoint inhibitors for metastatic breast cancer treatment. The study showed significant survival advantages over Trodelvy® and control groups:In triple negative breast cancer (TNBC), Bria-IMT achieved median overall survival of 13.9 months, surpassing Trodelvy (11.8 months) and doubling control group (6.9 months). For hormone receptor positive (HR+) patients, Bria-IMT reached 17.3 months median survival versus Trodelvy's 14.4 months and control's 11.2 months.The Phase 2 study included 54 heavily pre-treated patients who had received a median of 6 prior therapies. Notably, no Bria-IMT related treatment discontinuations were reported, and the company is currently conducting a pivotal Phase 3 study.

#BCTX #BCTXW #BCTXZ BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-s-br...

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient BriaCell Therapeutics (NASDAQ: BCTX) has reported significant progress in its Phase 2 study of Bria-IMT™ immunotherapy for advanced metastatic breast cancer. A patient who had previously failed 8 prior treatment regimens has shown remarkable results after 18+ months of treatment, including complete resolution of temporal lobe brain metastasis and continued reduction of orbital tumor that had caused eye bulging.The patient has completed 29 treatment cycles over 21 months, with serial imaging at 8, 11, and 20 months confirming no detectable disease in the right temporal lobe and continued response in the orbital lesion. Tumor markers have remained significantly reduced from baseline, supporting the sustained radiologic response.

#BCTX #BCTXW #BCTXZ BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

www.stocktitan.net/news/BCTX/bria-cell-repo...

Breakthrough: BriaCell's Cancer Therapy Eliminates Lung Metastasis in Advanced Breast Cancer Patient Novel immunotherapy Bria-OTS shows complete tumor elimination in metastatic breast cancer patient. Sustained results at 6 months with no toxicity. See full data.

#BCTX #BCTXW #BCTXZ BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

www.stocktitan.net/news/BCTX/bria-cell-pati...

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer BriaCell Therapeutics (NASDAQ: BCTX) has reported impressive survival data from its Phase 2 clinical study of Bria-IMT in metastatic breast cancer patients. The study showed that 52% of the most recent 25-patient cohort survived beyond one year, surpassing current standard of care expectations. Notably, 11 patients remain alive, with two remarkable cases reaching 38.3 and 30.3 months of survival.The study included heavily pre-treated patients who had previously failed multiple therapies, including checkpoint inhibitors and antibody-drug conjugates. The median number of prior treatments was 6, and importantly, no treatment discontinuations related to Bria-IMT have been reported, suggesting a well-tolerated profile.

#BCTX #BCTXW #BCTXZ BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-phas...

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven BriaCell Therapeutics (NASDAQ: BCTX) has expanded its pivotal Phase 3 clinical trial for advanced metastatic breast cancer treatment by adding two major cancer centers: Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, contributing 30 additional satellite locations. The study now encompasses 58 active clinical sites across 15 states.The trial evaluates BriaCell's lead candidate Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice. Patient enrollment is expected to complete by late 2025 or early 2026, with potential top-line data release in H1-2026. The study's primary endpoint will analyze overall survival after 144 patient events, with positive results potentially leading to full approval and marketing authorization.

#BCTX #BCTXW #BCTXZ BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

www.stocktitan.net/news/BCTX/bria-cell-high...

Major Breakthrough: FDA Fast-Track Breast Cancer Treatment Passes Critical Safety Review Latest DSMB review confirms safety profile of novel immunotherapy for metastatic breast cancer. See trial progress under FDA Fast Track designation.

#BCTX #BCTXW #BCTXZ BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

www.stocktitan.net/news/BCTX/bria-cell-anno...

BriaCell Therapeutics Opens Direct Access: Two Key Investor Presentations Announced for Cancer Immunotherapy Updates Register now for BriaCell's exclusive investor presentations on cancer immunotherapy developments. Join live sessions June 12 & 26. Limited spots available. Save your seat.

#BCTX #BCTXW #BCTXZ BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

www.stocktitan.net/news/BCTX/bria-cell-anno...

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 BriaCell Therapeutics (NASDAQ: BCTX) presented robust clinical data at ASCO 2025, showcasing impressive results from their Bria-IMT and Bria-OTS studies in metastatic breast cancer. The Phase 2 study demonstrated a median Overall Survival of 17.3 months for patients treated with the Phase 3 formulation since 2022, surpassing comparable literature outcomes. The treatment showed clinical benefit across all breast cancer subtypes with a 55% overall clinical benefit rate, including 100% in HER2+, 55% in HR+/HER2-, and 45% in triple-negative breast cancer patients. Notably, the Phase 3 formulation patients experienced significantly improved survival (13.9 vs 6.93 months) compared to alternate formulation. The therapy demonstrated strong safety with no treatment-related discontinuations, and efficacy data matched or exceeded FDA-approved therapies in similar patient populations. The company continues its pivotal Phase 3 study and has initiated combination therapy in its Bria-OTS program.

#BCTX #BCTXW #BCTXZ BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

www.stocktitan.net/news/BCTX/bria-cell-repo...